By Ahmed El-Medany
In a case series of 23 male patients, by Montgomery et al (2021), myocarditis was identified within 4 days of administration of a COVID-19 vaccine.
20 out of 23 of these patients received a diagnosis of myocarditis following their second dose of mRNA COVID-19 vaccine. It is important to note that these episodes occurred against a backdrop of 2.8 million delivered doses of mRNA COVID-19 vaccine in the United States.
Furthermore, a case series by Rosner et al (2021) in Circulation, as reported on seven male patients (aged 19-39 years) who developed myocarditis-like symptoms after receiving their COVID-19 vaccination. Five received Pfizer/BioNTech’s mRNA vaccina, one received Moderna’s mRNA vaccina, and one received Johnson & Johnson’s non-mRNA vaccine. All symptoms resolved by hospital discharge; the mean length of hospital stay was 3 days.
In a related press release, the American Heart Association has stated that reports of vaccine-induced myocarditis should not dissuade people from getting vaccinated. “The American Heart Association continues to urge all adults and children ages 12 and older in the U.S. to receive a COVID-19 vaccine as soon as they can, as recommended by the CDC. Research continues to indicate that the COVID-19 vaccines are 91% effective at preventing severe COVID-19 infection and spreading the virus to others. In addition, the benefits of vaccination far exceed the very unusual risks,” the AHA said in the release.
“According to the CDC, fewer than 1,000 cases of myocarditis-like illnesses were reported as of May 31, 2021, and nearly 312 million doses of COVID-19 vaccines have been administered in the U.S. to date.”
More here:
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military | JAMA Cardiology | JAMA Network
Myocarditis Temporally Associated with COVID-19 Vaccination | Circulation (ahajournals.org)
